DMAb-2
Prevention of COVID-19
Phase 1Not Recruiting
Key Facts
About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a trailblazer in the DNA medicine field, leveraging its SynCon® and CELLECTRA® platform to develop next-generation immunotherapies. The company has a diverse clinical pipeline targeting HPV-related conditions, cancer, and infectious diseases, with a significant milestone being the FDA's acceptance of its first Biologics License Application (BLA) for INO-3107 in RRP. With a strong history of collaboration with government, academic, and industry partners, Inovio is strategically positioned to advance its platform and bring novel, potentially transformative treatments to market.
View full company profileTherapeutic Areas
Other Prevention of COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| Recombinant COVID-19 Vaccine (ZF2001) | Zhifei Biological Products | Approved |
| Novel Coronavirus mRNA Vaccine | Zhifei Biological Products | Clinical |
| COVID-19 Inactivated Vaccine (BBIBP-CorV) | Tiantan Bio | Approved |
| Recombinant COVID-19 Vaccine | Tiantan Bio | Phase 3 |
| MVA-BN (Multi-Variant) | Bavarian Nordic | Phase 2 |
| Oral COVID-19 Vaccine | Oramed Pharmaceuticals | Pre-clinical |
| DMAb-1 | Inovio Pharmaceuticals | Phase 1 |
| SARS-CoV-2 Vaccine | Auro Vaccines | Poised for Clinical |